Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07132177 · ClinicalTrials.gov registry record · Phase 2
Targeted Naltrexone to Support Individuals Participating in Dry January
A Phase 2 study of Alcohol Misuse, sponsored by Brigham and Women's Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT07132177 is a Phase 2 study of Alcohol Misuse that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 20 participants, below the 1,622-participant average among 8 other Alcohol Misuse trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07132177, a Phase 2 study of Alcohol Misuse, is actively recruiting participants, sponsored by Brigham and Women's Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot open-label study will assess the feasibility, acceptability, and preliminary efficacy of targeted (as-needed) oral naltrexone in individuals participating in "Dry January," a month-long voluntary abstinence or reduction in alcohol use. Participants who do not meet criteria for alcohol use disorder (AUD) but are interested in reducing or abstaining from alcohol will receive a 31-day supply of 50mg oral naltrexone to take either prior to anticipated drinking or daily as a precaution. The study will evaluate recruitment, retention, adherence, and safety, as well as changes in alcohol use patterns, craving, mood, liver function, and quality of life. A qualitative interview at follow-up will explore participants' experiences using naltrexone during Dry January. Results will inform future randomized trials testing low-intensity, scalable interventions for non-treatment-seeking individuals seeking to reduce alcohol consumption.
Conditions Studied
Interventions
- DRUG Naltrexone (oral tablets)
Study Locations (1)
Massachusetts
- Brigham and Women's hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-11-03 |
| Est. Completion | 2026-05-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07132177
The ClinicalTrials.gov registry entry for NCT07132177 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,622-participant average among 8 other Alcohol Misuse trials with a reported enrollment target (99% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alcohol Misuse appearing as the primary indexed condition, and to 1 intervention - of which Naltrexone (oral tablets) is the first listed.
NCT07132177 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07132177 about?
NCT07132177 is a clinical study titled "Targeted Naltrexone to Support Individuals Participating in Dry January". This pilot open-label study will assess the feasibility, acceptability, and preliminary efficacy of targeted (as-needed) oral naltrexone in individuals participating in "Dry January," a month-long voluntary abstinence or reduction in alcohol use. Participants who do not meet criteria for alcohol use...
What is the current status of trial NCT07132177?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2025-11-03. Estimated completion is 2026-05-01.
What conditions does trial NCT07132177 study?
This clinical trial studies the following conditions: Alcohol Misuse.
What interventions are being tested in trial NCT07132177?
The interventions under investigation include: Naltrexone (oral tablets) (DRUG).
Who is sponsoring clinical trial NCT07132177?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07132177 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Misuse
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy of a Smartphone-Based JITAI to Reduce Drinking Among Adults Experiencing Homelessness
RECRUITING · Phase 2
-
Transition Health and Resilience Through Valued Experiences (THRiVE) Pilot for Newly Separated Veterans
RECRUITING · NA
-
MiREA-AC for Reducing Problematic Alcohol and Marijuana Use in College Students
RECRUITING · NA
-
Gathering Online for Dialogue and Discussion to Enhance Social Support
RECRUITING · NA
-
Telehealth Treatment of Veterans With Alcohol Misuse at Risk for Cardiovascular Disease
ACTIVE NOT RECRUITING · NA
-
Evaluating Cross-Cutting Prevention at the U.S. Air Force Academy
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.